Seramun Diagnosticas SeraSpot®Anti-SARS-CoV-2 IgG test was part of a vaccination study carried out by the Charité Berlin, Germany, from December 2020 to May 2021. The results of this study have now been published (https://www.medrxiv.org/content/10.1101/2021.05.19.21257334v2.full.pdf). It was shown that a heterologous ChAdOx / BNT vaccination with intervals of 10-12 weeks is well tolerated and just as immunogenic as a homologous BNT / BNT vaccination.
SARS-CoV-2-specific antibodies presence was examined with the SeraSpot®Anti-SARS-CoV-2 IgG - a microarray-based immunoassay - which comprises various SARS-CoV-2-specific antigens to distinguish between vaccine-induced antibody response and convalescent infection. Seramun is proud to contribute with its products to fighting against.